Redx Joins Forces With Jounce To Form $425m Cancer And Fibrosis Company
Nabs NASDAQ Listing
After a rollercoaster of a journey to date, UK firm Redx unveiled plans to merge with US biotech Jounce in a deal that would create a $425m transatlantic company with a robust cash runway through to 2025.
You may also be interested in...
Gilead Waives Acquisition Option As Pionyr Explores Other Strategies
Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.
SVB UK’s Rescue Good News For Europe’s Fragile Biotech Sector
The British government helped secure HSBC as a buyer for SVB UK, but sector leaders want to see more support in the shape of sustained R&D tax relief.
Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.